AsiaMedic Limited: FY2025 Financial Audit Review and Key Variances
AsiaMedic Limited has released details regarding material variances between its unaudited financial results announced on 1 March 2026 and its audited financial statements for the financial year ended 31 December 2025. This article analyzes the nature and impact of these differences, summarizes key findings, and provides actionable guidance for investors.
Key Financial Metrics and Variances
The most significant variances in AsiaMedic’s FY2025 financials stem from the disposal and deconsolidation of a subsidiary, intercompany elimination adjustments, and reclassification within equity. These are summarized below:
| Metric |
Audited FY2025 |
Unaudited FY2025 |
Variance (S\$) |
Variance (%) |
| Other Income |
1,698,244 |
818,733 |
879,511 |
107% |
| Impairment loss on financial assets – associate |
– |
(1,030,873) |
1,030,873 |
100% |
| Gain from deconsolidation of subsidiary |
– |
1,682,784 |
(1,682,784) |
(100%) |
| Gain from disposal of subsidiary |
– |
227,600 |
(227,600) |
(100%) |
Notably, the audited results combined the gain on deconsolidation, the gain on disposal, and the related impairment of receivables into a single “Other income” line, whereas the unaudited results had presented them separately. This reclassification resulted in a significant increase in “Other income” in the audited statements.
Balance Sheet Reclassifications
| Metric |
Audited FY2025 |
Unaudited FY2025 |
Variance (S\$) |
Variance (%) |
| Other Receivables & Deposits (Group) |
1,784,002 |
1,274,388 |
509,614 |
40% |
| Other Payables & Accruals (Group) |
3,448,112 |
2,938,498 |
509,614 |
17% |
| Other Reserves (Group) |
137,210 |
(515,334) |
652,544 |
127% |
| Accumulated Losses (Group) |
(16,823,141) |
(17,475,685) |
652,544 |
(4%) |
| Other Receivables & Deposits (Company) |
4,665,726 |
3,634,852 |
1,030,874 |
28% |
| Accumulated Losses (Company) |
(19,603,762) |
(20,634,636) |
1,030,874 |
(5%) |
Summary and Explanatory Notes on Variances
-
Disposal of AsiaMedic Astique The Aesthetic Company (AATAC): The group disposed of 60% interest in AATAC on 31 October 2025, resulting in AATAC becoming an associate and its deconsolidation from the Group. Gains and related impairments were netted in “Other income” in the audited results for clarity.
-
Intercompany Elimination Adjustments: Corrections in over-elimination of intercompany balances led to equivalent adjustments in receivables and payables, with no impact on net assets or profit.
-
Equity Reclassification: A reclassification of put option reserves to accumulated losses occurred, affecting presentation but not total equity.
-
Reversal of Impairment (Company Level): The Company reversed an impairment loss on amounts owed by an associate, increasing receivables and reducing accumulated losses, thereby boosting the Company’s profit.
Exceptional Earnings and Expenses
The main exceptional item is the disposal and deconsolidation of AATAC, which led to significant one-off gains and related accounting adjustments. These were consolidated into “Other income” in the audited accounts for FY2025.
Divestments and Corporate Actions
AsiaMedic completed the sale of a controlling stake in AATAC, which is a material event. This strategic divestment has altered the Group’s structure and resulted in one-off income statement effects.
Errors, Corrections, and Presentation Changes
All variances between unaudited and audited results were due to final audit adjustments, mainly reclassification and elimination corrections. There is no evidence of error in underlying performance, but the magnitude of reclassifications indicates the importance of careful audit procedures.
Conclusion and Outlook
Overall Financial Performance and Outlook: The Group’s FY2025 results are heavily influenced by one-off accounting adjustments related to the disposal of a subsidiary. While these boost reported income and reduce accumulated losses, they are not reflective of recurring operating performance. The underlying business appears stable, but investors should be cautious of relying on exceptional gains for future earnings expectations.
Investor Recommendations
-
If you are currently holding the stock: Consider maintaining a cautious stance. The exceptional income recognized is non-recurring, and future earnings may normalize without similar one-off events. Monitor the company’s core operating performance in upcoming quarters.
-
If you are not holding the stock: It is advisable to wait for more clarity on sustained operating profitability, as the FY2025 results are distorted by one-off items. Avoid initiating a new position solely based on the improved FY2025 bottom line.
Disclaimer: This analysis is based strictly on information provided in the FY2025 audit variance announcement. It does not constitute investment advice. Investors should consult their own financial advisers and review the full annual report before making any investment decision.
View AsiaMedic Historical chart here
